Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06077838 · ClinicalTrials.gov registry record · NA
RELAXaHEAD for Headache Patients (Phase III)
A NA study of Migraine, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 356
- Enrollment target
- 1
- Study location
NCT06077838: Recruiting NA study of Migraine, sponsored by NYU Langone Health.
NCT06077838 is a NA study of Migraine that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 356 participants, roughly in line with the 355-participant average among 102 other Migraine trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06077838, a NA study of Migraine, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 356 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.
Primary Outcome
5-item scale designed to measure disability over the previous 4 weeks. The total score is the sum of missed days due to a migraine from paid work, school, housework, and nonwork (family, social, and leisure) activities and days at paid work or housework where productivity was reduced by at least half. A decrease in scores indicates disability decreased during the observational period.
Conditions Studied
Interventions
- BEHAVIORAL RELAXaHEAD Smartphone App Version 1
- BEHAVIORAL RELAXaHEAD Smartphone App Version 2
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2028-08-31 |
| Phase | NA |
What NCT06077838 shows while recruiting
NCT06077838 is an interventional study that assigns participants to a tested intervention. The registered 356 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 355-participant average among 102 other Migraine trials with a reported enrollment target.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which RELAXaHEAD Smartphone App Version 1 is the first listed.
NCT06077838 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06077838 about?
NCT06077838 is a clinical study titled "RELAXaHEAD for Headache Patients (Phase III)". This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.
What is the current status of trial NCT06077838?
This trial is currently recruiting. It is a NA study. The enrollment target is 356 participants. The study started on 2023-11-08. Estimated completion is 2028-08-31.
What conditions does trial NCT06077838 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06077838?
The interventions under investigation include: RELAXaHEAD Smartphone App Version 1 (BEHAVIORAL), RELAXaHEAD Smartphone App Version 2 (BEHAVIORAL).
Who is sponsoring clinical trial NCT06077838?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06077838 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06077838's enrollment target sits among peer trials
356 30th of 102 higher than 73 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06960993 · 356 participants · NA
Mosaic Trial for Stem Cell Transplant Recipients
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI